Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

Recent Publications

Sperm very long-chain polyunsaturated fatty acids: relation to semen parameters and live birth outcome in a multicenter trial

Fertil Steril. 2023 May;119(5):753-760. doi: 10.1016/j.fertnstert.2023.01.020. Epub 2023 Jan 19.

ABSTRACT

OBJECTIVE: To determine whether the levels of sperm very long-chain polyunsaturated fatty acids (VLC-PUFAs) are correlated with sperm parameters and the outcome of live birth after conventional therapy for unexplained infertility.

DESIGN: Cohort analysis of the Reproductive Medicine Network's Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation randomized controlled trial.

SETTING: Multicenter randomized controlled trial.

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation

Ann Rheum Dis. 2023 May;82(5):670-680. doi: 10.1136/ard-2021-221926. Epub 2023 Jan 18.

ABSTRACT

OBJECTIVES: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective of this study was to test the hypothesis that transplantation stabilises the autoantibody repertoire in patients with favourable clinical outcomes.

Upcoming Events

Media

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies